Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Pancreatic Neoplasms 70Neoplasms 56Neoplasm Metastasis 32Brain Neoplasms 31Head and Neck Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Glioblastoma 24Adenocarcinoma of Lung 23Gliosarcoma 22Non-Squamous Non-Small Cell Lung Cancer 21Colorectal Neoplasms 18Carcinoma, Hepatocellular 17Adenocarcinoma, Bronchiolo-Alveolar 16Rectal Neoplasms 13Colonic Neoplasms 13Carcinoma, Renal Cell 13Glioma 12Esophageal Neoplasms 11Astrocytoma 11Central Nervous System Neoplasms 9Carcinoma, Squamous Cell 9Salivary Gland Neoplasms 8Prostatic Neoplasms 8Oligodendroglioma 8Gallbladder Neoplasms 8Adenocarcinoma 8Ovarian Neoplasms 7

Interventions

Vincristine 2Temozolomide 2Oncolytic Virotherapy 2vorasidenib 1repotrectinib 1pralsetinib 1pembrolizumab 1pamiparib 1lutetium Lu 177 dotatate 1interferon gamma-1b 1copper dotatate CU-64 1cixutumumab 1Vorinostat 1Valproic Acid 1Thiotepa 1Sunitinib 1Radiotherapy 1Radiation 1Peripheral Blood Stem Cell Transplantation 1ONC206 1Melphalan 1Maintenance Chemotherapy 1Lutetium-177 1Lutetium 1Lomustine 1Interleukin-12 1Interferon-gamma 1Immunotherapy 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors × Erlotinib Hydrochloride × Clear all
NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Washington University School of Medicine

Phase 2 Withdrawn
CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡